Skip to content
lifestyle.jardal-paintball.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Medicus Pharma Ltd
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
April 27, 2026
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
April 17, 2026
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
April 15, 2026
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
April 6, 2026
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
April 1, 2026
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
March 30, 2026
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
March 9, 2026
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
March 5, 2026
←
Previous Page
1
2
3
Next Page
→